Home » News » Drug Sponsors » Merz Pharma Group withdraws proposal to acquire Obagi

Merz Pharma Group withdraws proposal to acquire Obagi

Monday, April 8, 2013

Merz Pharma Group has withdrawn its non-binding proposal to acquire all of the outstanding common stock of Obagi Medical Products for $22 per share in cash.

The decision to withdraw the proposal follows the recent announcement that Valeant Pharmaceuticals International increased its offer to acquire Obagi from $19.75 to $24.00 per share in cash, pursuant to an amendment to the Valeant and Obagi Agreement and Plan of Merger, dated March 19, 2013.

“Obagi was an opportunity worth pursuing given its complementary fit with Merz’s portfolio of injectables,” said Philip Burchard, CEO of Merz. “However, Merz is a disciplined buyer and at this level the economics of such a transaction do not meet our requirements. We look forward to exploring other acquisition opportunities that fit our strategy. In addition, we will build on Merz’s strong position in the markets we serve and continue to invest in our own R&D.”

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!